BACKGROUND: The p53 gene is frequently mutated in various human tumours. In addition, single nucleotide polymorphisms are often observed in exons and introns of the p53 gene in normal tissues and tumours. MATERIALS AND METHODS: A total of 210 blood and tissue samples from 182 ovarian cancers (OC) and 28 ovarian borderline tumours, in addition to blood samples from 72 healthy women, were analysed. The used analyses were PCR and SSCP. The distinguishable SSCP patterns were confirmed by DNA sequencing. RESULTS: A polymorphism located at position 38 in intron 2 of the p53 gene was studied in blood and tumour tissues from Danish ovarian tumour patients and in blood from controls. Significant differences were found between the distributions of the genotypes in blood samples compared to the corresponding tissue samples (p = 0.0002). A tendency towards a significant difference in survival was observed between OC stage II patients with a shift from one genotype in the blood to another genotype in the tissue and patients with no shift (p = 0.05). In multivariate COX regression analysis restricted to stage III OC patients, the only independent factors found were shift, serum-tetranectin and age. CONCLUSION: A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancer patients.
BACKGROUND: The p53 gene is frequently mutated in various humantumours. In addition, single nucleotide polymorphisms are often observed in exons and introns of the p53 gene in normal tissues and tumours. MATERIALS AND METHODS: A total of 210 blood and tissue samples from 182 ovarian cancers (OC) and 28 ovarian borderline tumours, in addition to blood samples from 72 healthy women, were analysed. The used analyses were PCR and SSCP. The distinguishable SSCP patterns were confirmed by DNA sequencing. RESULTS: A polymorphism located at position 38 in intron 2 of the p53 gene was studied in blood and tumour tissues from Danish ovarian tumourpatients and in blood from controls. Significant differences were found between the distributions of the genotypes in blood samples compared to the corresponding tissue samples (p = 0.0002). A tendency towards a significant difference in survival was observed between OC stage II patients with a shift from one genotype in the blood to another genotype in the tissue and patients with no shift (p = 0.05). In multivariate COX regression analysis restricted to stage III OC patients, the only independent factors found were shift, serum-tetranectin and age. CONCLUSION: A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancerpatients.
Authors: Honglin Song; Estrid Hogdall; Susan J Ramus; Richard A Dicioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Susanne Kruger Kjaer; Paul D P Pharoah; Simon A Gayther Journal: Clin Cancer Res Date: 2008-02-15 Impact factor: 12.531
Authors: Andrea Mann; Estrid Hogdall; Susan J Ramus; Richard A DiCioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Bruce A J Ponder; Susanne Krüger Kjaer; Simon A Gayther; Deborah J Thompson; Paul D P Pharoah; Honglin Song Journal: Eur J Cancer Date: 2008-08-22 Impact factor: 9.162
Authors: Joellen M Schildkraut; Ellen L Goode; Merlise A Clyde; Edwin S Iversen; Patricia G Moorman; Andrew Berchuck; Jeffrey R Marks; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Julie M Cunningham; Robert A Vierkant; David N Rider; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Xiaoqing Chen; Catherine Phelan; Rebecca Sutphen; Thomas A Sellers; Leigh Pearce; Anna H Wu; David Van Den Berg; David Conti; Christopher K Elund; Rebecca Anderson; Marc T Goodman; Galina Lurie; Michael E Carney; Pamela J Thompson; Simon A Gayther; Susan J Ramus; Ian Jacobs; Susanne Krüger Kjaer; Estrid Hogdall; Jan Blaakaer; Claus Hogdall; Douglas F Easton; Honglin Song; Paul D P Pharoah; Alice S Whittemore; Valerie McGuire; Lydia Quaye; Hoda Anton-Culver; Argyrios Ziogas; Kathryn L Terry; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger; Brian Calingaert; Stephen Chanock; Mark Sherman; Montserrat Garcia-Closas Journal: Cancer Res Date: 2009-03-10 Impact factor: 12.701